The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer Samsara (IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting initial filings....read more
Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, raised $21 million by offering 4.2 million shares at $5, the low end of the range of $5 to $6. The company offered 0.4 million more shares than anticipated. Immix is...read more
Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, announced terms for its IPO on Wednesday.The Los Angeles, CA-based company plans to raise $21 million by offering 3.8 million shares at a price range of $5 to $6. At...read more
US IPO Weekly Recap: 6 IPOs debut ahead of the shortened holiday week
The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer Samsara (IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting initial filings....read more
Micro-cap oncology biotech Immix Biopharma prices IPO at $5 low end
Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, raised $21 million by offering 4.2 million shares at $5, the low end of the range of $5 to $6. The company offered 0.4 million more shares than anticipated. Immix is...read more
Oncology biotech Immix Biopharma sets terms for $21 million IPO
Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, announced terms for its IPO on Wednesday.The Los Angeles, CA-based company plans to raise $21 million by offering 3.8 million shares at a price range of $5 to $6. At...read more
US IPO Weekly Recap: The Fall IPO market is in full swing with an 11 IPO week
...read more